<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02731664</url>
  </required_header>
  <id_info>
    <org_study_id>PRANDMOTGLP</org_study_id>
    <nct_id>NCT02731664</nct_id>
  </id_info>
  <brief_title>GLP-1 Inhibits Prandial Antro-duodeno-jejunal Motility in Humans</brief_title>
  <acronym>GLPMOT</acronym>
  <official_title>GLP-1 Inhibits Prandial Antro-duodeno-jejunal Motility in Humans: Native GLP-1 Compared With Analogue ROSE-010 in Vitro</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The inhibitory effect of low dose GLP-1 is investigated on prandial motility of the stomach,
      duodenum and jejunum in vivo in humans. Supplementary in vitro studies on the mechanism of
      action of the GLP-1 inhibition of motility as carried out on muscle strips from the upper
      gastrointestinal tract in man.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twelve healthy volunteers will undergo antroduodenojejunal manometry. Baseline recording with
      infusion of saline for 1 hour is compared with infusion of GLP-1 0.7 and 1.2 pmol per kg
      minute for another 1 hour. Plasma GLP-1 and GLP-2 is measured by RIA. Responses to GLP-1 will
      be measured after food intake as prandial response to GLP-1. The outcome will be evaluated as
      change in motility index from baseline to meal-stimulated conditions and during influence of
      GLP-1. Further in vitro studies of gastrointestinal muscle strips, precontracted with
      bethanechol or electric field stimulation, are planned to investigate the response to GLP-1
      or GLP-1 analogue ROSE-010. GLP-1 and GLP-2 receptor immunoreactivity is localized by
      immunohistochemistry. Receptor mediated mechanisms are studied with GLP-1 receptor blocker
      exendin(9-39)amide, nitro-monomethyl arginine to block nitric oxide synthase and tetrodotoxin
      to block sodium channels and nerve conduction.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Motility index (measure of contraction amplitude x duration; area for mmHg x sec)</measure>
    <time_frame>60 minutes</time_frame>
    <description>Inhibition of prandially increased motility index (motor activity in the antrum and upper small intestine).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Smooth muscle relaxation induced by GLP-1</measure>
    <time_frame>6 hours</time_frame>
    <description>Separate experiments in vitro: GLP-1-induced inhibition of bethanechol-stimulated smooth muscle strips to characterize GLP-1's pharmacological action.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of GLP-1 and GLP-2 receptors in gastric and small bowel tissue</measure>
    <time_frame>1 day</time_frame>
    <description>Separate experiments in vitro: Antibody staining of gastric and small bowel tissue for receptors of GLP-1 and GLP-2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Functional Gastrointestinal Disorders</condition>
  <arm_group>
    <arm_group_label>GLP-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of GLP-1 at 0.7 and 1.2 mol/kg per minute</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GLP-1</intervention_name>
    <description>Intravenous infusion of GLP-1</description>
    <arm_group_label>GLP-1</arm_group_label>
    <other_name>Glucagon-like peptide-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intravenous saline</intervention_name>
    <description>Control</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers over 18 years of age.

        Exclusion Criteria:

          -  Any medical condition.

          -  Any drug treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per M. Hellström, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Per M. Hellström, MD, PhD</last_name>
    <phone>+46 18 611 4285</phone>
    <email>Per.Hellstrom@medsci.uu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dominic-Luc Webb, PhD</last_name>
    <phone>+46 18 471 4721</phone>
    <email>Dominic-luc.Webb@medsci.uu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uppsala University</name>
      <address>
        <city>Uppsala</city>
        <state>Uppsala county</state>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per M Hellstrom, MD, Prof</last_name>
      <phone>+46 70 3727423</phone>
      <email>Per.Hellstrom@medsci.uu.se</email>
    </contact>
    <contact_backup>
      <last_name>Dominic-Luc Webb, PhD</last_name>
      <phone>+46 18 4714721</phone>
      <email>Dominic-Luc.Webb@medsci.uu.se</email>
    </contact_backup>
    <investigator>
      <last_name>Per M Hellström, MD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Edholm T, Degerblad M, Grybäck P, Hilsted L, Holst JJ, Jacobsson H, Efendic S, Schmidt PT, Hellström PM. Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis. Neurogastroenterol Motil. 2010 Nov;22(11):1191-200, e315. doi: 10.1111/j.1365-2982.2010.01554.x.</citation>
    <PMID>20584260</PMID>
  </reference>
  <reference>
    <citation>Hellström PM, Hein J, Bytzer P, Björnssön E, Kristensen J, Schambye H. Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study. Aliment Pharmacol Ther. 2009 Jan;29(2):198-206. doi: 10.1111/j.1365-2036.2008.03870.x. Epub 2008 Oct 10.</citation>
    <PMID>18945254</PMID>
  </reference>
  <results_reference>
    <citation>Hellström PM, Näslund E, Edholm T, Schmidt PT, Kristensen J, Theodorsson E, Holst JJ, Efendic S. GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterol Motil. 2008 Jun;20(6):649-59. doi: 10.1111/j.1365-2982.2007.01079.x. Epub 2008 Feb 19.</citation>
    <PMID>18298441</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2016</study_first_submitted>
  <study_first_submitted_qc>April 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2016</study_first_posted>
  <last_update_submitted>August 2, 2016</last_update_submitted>
  <last_update_submitted_qc>August 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Uppsala University</investigator_affiliation>
    <investigator_full_name>Per Hellström</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Irritable bowel syndrome</keyword>
  <keyword>Functional dyspepsia</keyword>
  <keyword>Gastric emptying</keyword>
  <keyword>Gastrointestinal peptide hormones</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>On request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

